New article in THE LANCET
2020 July
Autors :
Charles-Hugo Marquette, Jacques Boutros, Jonathan Benzaquen, Marion Ferreira, Jean Pastre, Christophe Pison, Bernard Padovani, Faiza Bettayeb,
Vincent Fallet, Nicolas Guibert, Damien Basille, Marius Ilie, Véronique Hofman, Paul Hofman, on behalf of the AIR project Study Group†
Summary:
Background Lung cancer screening with low-dose chest CT (LDCT) reduces the mortality of eligible individuals. Blood
signatures might act as a standalone screening tool, refine the selection of patients at risk, or help to classify
undetermined nodules detected on LDCT. We previously showed that circulating tumour cells (CTCs) could be
detected, using the isolation by size of epithelial tumour cell technique (ISET), long before the cancer was diagnosed
radiologically. We aimed to test whether CTCs could be used as a biomarker for lung cancer screening.